Knowledge Ecology International (KEI) has sent a letter to Katherine Vidal, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO) concerning an issue in Article 3 of the the World Intellectual Property… Continue Reading
On October 3, 2023, Knowledge Ecology International (KEI) sent a letter to the FDA asking the agency to publish its historical Orange Book data. The Orange Book identifies patent and exclusivity data for FDA approved drug products. The FDA publicly… Continue Reading
On September 3, 2024, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases” (89 FR 66730). The Federal Register notice… Continue Reading
On July 17, 2024, Knowledge Ecology International (KEI) joined Universities Allied for Essential Medicines, Dr. Christopher Morten, and Dr. Reshma Ramachandran in submitting an amicus brief in the case of the Center for Investigative Reporting, et al. v. United States… Continue Reading
Knowledge Ecology International (KEI) offered the following comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors” (89 FR 40495) to McSAF Inside Oncology SAS (McSAF).… Continue Reading
On Tuesday June 4, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding “Prospective Grant of an Exclusive Patent License: T Cell Receptor Fusion Proteins for the Treatment of Cancer” (89 FR 43859) to… Continue Reading
On May 15, 2024, Health Policy Watch published the latest draft (as of May 10, 2024) of the WHO Pandemic Accord by the Intergovernmental Negotiating Body (INB). In order to provide a better understanding of what is and is not… Continue Reading
On May 15, 2024, Knowledge Ecology International published an article on “Sanctions for Non Disclosure, as Set Out in Article 6 of the WIPO Basic Proposal on Intellectual Property, Genetic Resources and Traditional Knowledge, Should Include Possible Revocation of a… Continue Reading
On April 8, 2024, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the prospective grant of an exclusive license to Poolbeg Pharma Limited, a UK-based company. The license concerns, “Adoptive T Cell Therapy Products… Continue Reading
Today Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Vaccine Augmented Adoptive Cell Therapy for the Treatment of Cancer” (89 FR 8438). The wordwide, exclusive license… Continue Reading